002173 Innovative Medical Management
- 7.80
- +0.04+0.52%
Innovative Medical Management News
Hong Kong Stock Concept Tracking | New Advances in Brain-Computer Interface Technology! Neuralink begins recruiting a second patient (with concept stock)
Musk announced that after 100 days of successful surgery for the first patient involved in the brain-computer device implantation experiment at the beginning of the year, Neuralink (Neuralink) has officially begun recruiting a second patient to receive a brain-computer implantation.
Innovative Healthcare (002173.SZ): Net loss of 2,977,900 yuan in the first quarter
On April 26, Ge Longhui | Innovative Healthcare (002173.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 201 million yuan, down 1.40 from the previous year; net profit attributable to shareholders of listed companies - RMB 2,977,900; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses - RMB 2.7087 million; and basic earnings per share - 0.0067 yuan.
Innovative Healthcare (002173.SZ): Net loss of 34.2877 million yuan in 2023
On April 12, Ge Longhui (002173.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 806 million yuan, an increase of 13.51% over the previous year; net profit attributable to shareholders of listed companies was -34,287,700 yuan; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was -280.26 million yuan; and basic earnings per share -0.08 yuan.
Sanxin Medical (300453.SZ): The products of the holding subsidiary passed the innovative medical device review
Sanxin Medical (300453.SZ) announced that recently, Jiangxi Colevide Biotechnology Co., Ltd., a holding subsidiary of the company...
Aibo Healthcare (688050.SH): Product passed a special review process for innovative medical devices
Gelonghui, April 2 | Aibo Medical (688050.SH) announced that the company's “artificial lens” recently passed the Special Examination Procedure for Innovative Medical Devices by the Medical Device Technology Review Center of the State Drug Administration (Innovation Review Acceptance Number: CQTS2400048). This product is an artificial lens with the effect of extending depth of field. While providing farsightedness comparable to that of ordinary single-focus intraocular lenses, patients can benefit from useful medium- and near-vision. Currently, all domestic depth-of-field intraocular lens products rely on imports. The extended depth of field intraocular lens products developed by the company is based on many innovations
Innovative Medical ManagementLtd (SZSE:002173) Shareholders Are Still up 35% Over 3 Years Despite Pulling Back 9.2% in the Past Week
One simple way to benefit from the stock market is to buy an index fund. But many of us dare to dream of bigger returns, and build a portfolio ourselves. For example, Innovative Medical Management C
Guojin Securities: Medical equipment updates are expected to accelerate demand for high-end innovative medical equipment is expected to be released
It is recommended to focus on segments such as surgical robotics, endoscopes, ultrasound, and ICU equipment.
Concept Nuggets | China's brain-computer interface has achieved technological breakthroughs. Which companies are worth deploying?
Great potential for development
Innovative Medical Management Co.,Ltd. (SZSE:002173) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Innovative Medical Management Co.,Ltd. (SZSE:002173) shareholders are no doubt pleased to see that the share price has bounced 26% in the last month, although it is still struggling to make up recentl
The idea controls the mouse, a new breakthrough in brain-computer interface! Musk's grand ambitions are not far off
Brain-computer interface+AI, full of buffs!
Is Innovative Medical ManagementLtd (SZSE:002173) Weighed On By Its Debt Load?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' When we think about how
Innovative Healthcare (002173.SZ): Pre-loss of 25 million yuan to 35 million yuan in 2023
Gelonghui, January 30 | Innovative Healthcare (002173.SZ) announced its 2023 annual results forecast. Net profit loss attributable to shareholders of listed companies during the reporting period was 35 million yuan to 25 million yuan, loss of 73.6972 million yuan for the same period of the previous year; net profit loss after deducting non-recurring profit and loss of 34 million yuan to 24 million yuan, loss of 84.206 million yuan for the same period last year; basic earnings loss per share of 0.08 yuan/share — 0.06 yuan/share; operating income of 80 million yuan to 82 million yuan. The company's net profit attributable to shareholders of listed companies during the reporting period
Innovative Healthcare (002173.SZ): Plans to increase capital of Futian Hospital by 10 million yuan
Gelonghui, January 26, 丨 Innovative Healthcare (002173.SZ) announced that the first interim meeting of the sixth board of directors in 2024 held by the company on January 26, 2024 reviewed and passed the “Proposal on Using Own Funds to Increase the Capital of Futian Hospital”. In view of the actual situation of the company's subsidiary, Jiangsu Futian Rehabilitation Hospital Co., Ltd. (“Futian Hospital”), in order to optimize its capital structure, the company decided to use its own capital to increase the capital of Futian Hospital by 10 million yuan.
Innovative Medical Management Co.,Ltd.'s (SZSE:002173) Market Cap Dropped CN¥432m Last Week; Individual Investors Bore the Brunt
Key Insights The considerable ownership by individual investors in Innovative Medical ManagementLtd indicates that they collectively have a greater say in management and business strategy The top 17
Xiansheng Pharmaceutical (02096.HK): Plans to acquire all shares in Nanjing Baijiahui Innovative Medical Technology for 42.3065 million yuan
Gelonghui, January 1, 丨 Xiansheng Pharmaceutical (02096.HK) announced that on January 1, 2024, the buyer (an indirect wholly-owned subsidiary of the company) signed an equity transfer agreement with the seller. According to this, the buyer agreed to buy and the seller agreed to sell all of the shares in the target company Nanjing Baijiahui Innovative Medical Technology. The cash cost was RMB 42.3065 million. After the acquisition is completed, the target company will become an indirect wholly-owned subsidiary of the company, and the target company's financial results will be incorporated into the group's financial statements. According to reports, the target company is a limited liability company established in China on July 10, 2017
Recent 8.2% Pullback Isn't Enough to Hurt Long-term Innovative Medical ManagementLtd (SZSE:002173) Shareholders, They're Still up 26% Over 1 Year
The simplest way to invest in stocks is to buy exchange traded funds. But you can significantly boost your returns by picking above-average stocks. For example, the Innovative Medical Management Co.
Innovative Healthcare (002173.SZ) Director Ruan Guangyin completed the reduction of the company's shares by 199,300 shares
Innovative Healthcare (002173.SZ) announced that director Ruan Guangyin of the company reduced his holdings of the company's shares by a total of 199,300 shares,...
Is Innovative Medical ManagementLtd (SZSE:002173) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
Innovative Healthcare (002173.SZ) released the first three quarter results, with a net loss of 142.14,800 yuan
Innovative Healthcare (002173.SZ) released the first three quarter reports. During the reporting period, the company achieved operating income of 6.07...
Huaan Securities: Optimistic about Jianshi Technology-B, the first major tricuspid product, is expected to be rated “buy” for the first time
Huaan Securities released a research report stating that Jianshi Technology-B (09877) is expected to reach 25.8 million yuan, 229 million yuan, and 619 million yuan respectively in 2023-2025, with year-on-year increases of 788.2% and 170.1% year-on-year in 2024-25. For the first time, it was covered and given a “buy” rating. Once the company's tricuspid business is commercialized, it will result in a rapid breakthrough on the revenue side, strong profit expectations, and extremely high growth potential. The first tricuspid valve replacement product is a major global FIC innovative medical device. The market potential is huge and the competition pattern is good. The bank is optimistic about the company's ability to quickly commercialize to bring about revenue breakthroughs
Analysis
Price Target
No Data
